16th ESMO World Congress on Gastrointestinal Cancer

Oncology Meeting Resources

25 Jun - 28 Jun, Barcelona, Spain

World GI 2013

New findings, new techniques, and recent efforts in research and discovery have changed the way physicians treat their patients - taking a more individualised approach. The 16th ESMO World Congress on Gastrointestinal Cancer provided important clinical updates in the management of patients.

Here, you will find the abstracts, PDF presentation and webcasts from World GI 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Search Meeting Resources by Keyword

Useful links

Presenter Presentation title Session title
Powel H. Brown Keynote Lecture 1: Prevention of colorectal cancer: State of the science and treatment recommendations Report from the ISCAP International Conference on GI Cancer Prevention
J. Evans O-0001 - Phase 2 double-blind, placebo–controlled trial of dasatinib added to gemcitabine for subjects with locally-advanced pancreatic cancer (LAPC) Cancer of the pancreas and bile ducts
Margaret Tempero Familial pancreatic cancer Cancer of the pancreas and bile ducts
D. Vernerey O-0002 - Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): an ancillary study of the LAP 07 trial Cancer of the pancreas and bile ducts
Daniel Von Hoff O-0003 - NAPOLI-1: randomized phase 3 study of MM-398 (nal-iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy Cancer of the pancreas and bile ducts
Herbert Hurwitz O-0026 - Results from a phase 2 study of ruxolitinib or placebo with capecitabine as second-line therapy in patients with metastatic pancreatic cancer: the RECAP trial Cancer of the pancreas and bile ducts
Manuel Hidalgo O-0004 - SPARC analysis in the phase III MPACT trial of nab-paclitaxel (nab-p) plus gemcitabine (gem) vs gem alone for patients with metastatic pancreatic cancer (pc) Cancer of the pancreas and bile ducts
Pascal Hammel Intraductal papillary mucinous neoplasm Cancer of the pancreas and bile ducts
Markus Büchler Surgical resection for pancreatic cancer: Anything new on the horizon? Cancer of the pancreas and bile ducts
Christophe Louvet What is the optimal treatment for patients with metastatic pancreatic cancer? Cancer of the pancreas and bile ducts
Eileen M. O'Reilly What is the optimal treatment for patients with metastatic pancreatic cancer? Cancer of the pancreas and bile ducts
Guy Berchem Clinical case discussion Cancer of the pancreas and bile ducts
Malcolm J. Moore New agents on the horizon in pancreatic cancer Cancer of the pancreas and bile ducts
Manuel Hidalgo Personalized medicine: The future in pancreatic cance Cancer of the pancreas and bile ducts
Jacques J. Bergman Treatment of Barrett’s esophagus: Update on new endoscopic modalities Cancer of the pancreas and bile ducts